Corcept Therapeutics announced it will host a presentation at the American Association of Clinical Endocrinologists meeting.
Corcept Therapeutics (NASDAQ:CORT) announced it will host a presentation at the Annual Congress of the American Association of Clinical Endocrinologists meeting on hypercortisolism and mifepristone’s role treating oncologic and psychiatric disorders.
As quoted in the press release:
“There is growing awareness that even less severe degrees of hypercortisolism are harmful,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “As a result, physicians are increasingly screening patients whose metabolic and cardiovascular symptoms have not responded to conventional therapy and finding cases of previously undetected Cushing’s syndrome.”
In addition to viewing the posters described below, AACE attendees may attend “Evolving Paradigms of Hypercortisolism,” a product theater talk by Ty Carroll, M.D. Corcept is a sponsor of the talk.